

STUDY PROTOCOL

Open Access



The effect of spironolactone on calcineurin inhibitor induced nephrotoxicity: a multicenter randomized, double-blind, clinical trial (the SPIREN trial)

Line Aas Mortensen^{1,2*}, Helle C. Thieson^{1,2}, Birgitte Tougaard³, Martin Egjford⁴, Anne Sophie Lind Fischer⁵ and Claus Bistrup^{1,2}

Abstract

Background: Calcineurin inhibitor induced nephrotoxicity contributes to late allograft failure in kidney transplant patients. Evidence points towards aldosterone to play a role in the development of fibrosis in multiple organs. Animal studies have indicated a beneficial effect of mineralocorticoid receptor antagonists preventing calcineurin inhibitor induced nephrotoxicity. Only few studies have explored this effect in humans. The objective of this study is to evaluate the effect of spironolactone on glomerular filtration rate and fibrosis in kidney transplant patients.

Method: Prospective, double-blind, randomized, clinical trial including 170 prevalent kidney transplant patients. Patients are randomized to spironolactone 25–50 mg/day or placebo for three years. Primary outcome is glomerular filtration rate evaluated by chrome-EDTA clearance. Secondary outcomes are 24-h protein excretion, amount of interstitial fibrosis in renal allograft biopsies, and cardiovascular events. As an exploratory outcome, we aim to identify markers of fibrosis in blood and urine.

Discussion: Long term allograft survival remains a key issue in renal transplantation, partly due to calcineurin inhibitor induced nephrotoxicity. Evidence from animal- and small human studies indicate a beneficial effect of mineralocorticoid receptor antagonism on renal function and fibrosis. This study aims to test this hypothesis in a sufficiently powered randomized clinical trial. Results might influence the future management of long term allograft survival in renal transplantation.

Trial registration: ClinicalTrials.gov identifier (05/17/2012): [NCT01602861](https://clinicaltrials.gov/ct2/show/study/NCT01602861). EudraCT number (05/31/2011): 2011–002243–98.

Keywords: Aldosterone, Mineralocorticoid, Kidney transplantation, Cyclosporine A, Tacrolimus, IFTA, Fibrosis, Glomerular filtration rate

Background

Background and rationale

The introduction of calcineurin inhibitors (CNI) cyclosporine and tacrolimus as part of immunosuppressive regimens in kidney transplantation has significantly improved short term allograft survival and function [1, 2], but continuous exposure to CNI can result in renal fibrosis ultimately

leading to chronic allograft failure. CNI nephrotoxicity is partly caused by vasoconstriction, thereby reducing renal blood flow and inducing oxidative stress, but also CNI directly increase the pro-fibrotic factor transforming growth factor β (TGF- β), apoptosis and macrophage infiltration [3]. Early reports indicated a prevalence of chronic CNI nephrotoxicity of up to 100% after 10 years of cyclosporine treatment [4], although a recent follow up has indicated less nephrotoxicity of modern, tacrolimus-based immunosuppressive protocols [5]. Nevertheless, improving long term allograft function remains a key challenge in renal transplantation.

* Correspondence: line.mortensen@rsyd.dk

¹Department of Nephrology, Odense University Hospital, Sdr. Boulevard 29, DK-5000 Odense C, Denmark

²Department of Clinical Research, University of Southern Denmark, Winsløwparken 19, 3. Sal, 5000 Odense C, Denmark

Full list of author information is available at the end of the article



The mineralocorticoid hormone aldosterone contributes to deleterious pro-fibrotic processes in several organs, including the kidneys [6, 7]. Aldosterone exerts its effects partly via the intracellular mineralocorticoid receptor (MR). Signaling via the MR regulates salt- and water balance, but also prompts inflammation, vasoconstriction and oxidative stress, which ultimately leads to tissue fibrosis [7]. Several large scale studies in congestive heart failure have highlighted the beneficial effect of MR antagonism on survival [8, 9] – partly explained by decreased myocardial fibrosis [10]. In chronic kidney disease, MR antagonism has shown beneficial effects reducing proteinuria, but no study has been sufficiently powered to investigate the effect on kidney function [11]. Evidence from animal models of CNI nephrotoxicity suggests a beneficial effect of MR antagonism on renal blood flow [12, 13], glomerular filtration rate (GFR) [12–18] and renal fibrosis [15–18].

Only a few studies have explored the potential of MR antagonism in kidney transplant recipients. A recent randomized clinical trial included 24 pediatric kidney transplant patients with biopsy-proven chronic allograft nephropathy and did not find a significant effect of eplerenone for 24 months versus placebo regarding GFR, proteinuria and fibrosis. The study was, however, underpowered [19]. One open-label study of 11 kidney transplant patients found significantly reduced levels of proteinuria after 6 months of spironolactone treatment despite unaltered blood pressure [20]. These findings were supported by a retrospective cohort study of 140 proteinuric kidney transplant patients concurrently treated with spironolactone [21]. Additionally, it has been shown that eplerenone given one day before and three days after the transplantation reduces markers of oxidative stress related to ischemia/reperfusion [22]. Hence, current evidence points towards beneficial effects of MR antagonism in kidney transplant patients. This remains to be confirmed in a sufficiently powered prospective trial.

Objectives and design

The SPIREN trial is an investigator initiated nationwide, multicenter, randomized, double-blind, placebo-controlled clinical trial designed to test the hypothesis that addition of the MR-antagonist spironolactone to standard therapy in prevalent kidney transplant patients will improve long term kidney function and reduce allograft fibrosis.

Methods

One hundred seventy kidney transplant patients will be included from four Danish hospitals covering all Danish renal transplant centers (Odense, Copenhagen and Aarhus). Patients are recruited from outpatient clinics in the Departments of Nephrology at Odense University Hospital, Kolding Hospital, Rigshospitalet, Copenhagen and Aarhus

University Hospital, respectively. Eligibility criteria are listed in Table 1.

Wide eligibility criteria have been chosen to obtain a high generalizability of the results. This study includes renal transplant patients with a stable kidney function at the time of inclusion. Even in stable patients, a gradual deterioration of renal function is expected. Previous studies have found an average rate of decline of glomerular filtration rate in of 1–3 mL/min/year [23–26]. Hence, we chose a follow up of 3 years.

Patients are randomized 1:1 to spironolactone (Spirix®) or placebo for three years. Initial dosage is 25 mg once daily, which is doubled after three months, if tolerated well. At inclusion and yearly hereafter a standard workup is performed including chrome-EDTA clearance, 24-h urine collection, electrocardiogram, 24-h ambulatory blood pressure measurement and blood- and urine samples (Fig. 1). Anonymized samples are stored at –80 °C until analyses. In a subgroup ($n = 50$) graft biopsies will be performed at inclusion and after two years. All registered variables are listed in Table 2.

Side effects, adverse events and compliance to the study drug are evaluated at project visits every three months. Compliance is evaluated by counting tablets.

Outcome

Outcomes are summarized in Table 3.

The primary endpoint is renal function evaluated by chrome-EDTA clearance, in which glomerular filtration rate is calculated from the area under the plasma clearance curve after a single intravenous doses of $^{51}\text{CrEDTA}$. Plasma concentrations of $^{51}\text{CrEDTA}$ can be determined with a single blood sample by measuring residual radioactivity 4 h after the injection or by multiple samples 4, 5 and 6 h after the injection. For centers using a single blood sample after 4 h, an additional blood sample is performed 24 h after the injection in male patients with plasma creatinine ≥ 200 $\mu\text{mol/L}$ and female patients with plasma

Table 1 Eligibility criteria

Inclusion criteria	Exclusion criteria
Age > 18 years	Former intolerance of spironolactone
Tacrolimus/cyclosporine treatment	Potassium binder or digoxin treatment
Proteinuria < 3 g/day	Pregnancy or planned pregnancy
Creatinine clearance ≥ 30 mL/min	Clinically relevant organic, systemic or psychological disorder
Plasma potassium < 5.5 mmol/L	Expectation of non-compliance
Negative pregnancy test at inclusion for women of childbearing potential and adequate contraception throughout the trial	



Fig. 1 Participant timeline

creatinine ≥ 150 $\mu\text{mol/L}$. In repeat chrome-EDTA clearance measurements the coefficient of variation is 8–10% [27].

Secondary endpoints include 24-h urinary protein excretion, cardiovascular events (death, myocardial infarction, stroke or peripheral arterial thrombosis) and renal fibrosis. For the latter, Masson Trichrome stained sections of kidney allograft biopsies will be used for measuring Banff chronicity scores and calculating morphologic fibrosis by point counting. Point counting provides a quantitative and reproducible estimation of the extent of fibrosis [28]. In brief, the software systematically selects sections of renal cortex and superimposes a grid on a computerized image. The extent of fibrosis is determined by counting the fraction of intersection points that overlie fibrotic areas relative to normal tissue. Limitations of both Banff scoring and point counting are the risk of sampling error as well as the somewhat subjective evaluation of fibrosis. In this study all biopsies will be reviewed by the same pathologist to avoid inter-observer variability.

As an exploratory outcome we aim to identify possible biomarkers of fibrosis in blood and urine. Kidney fibrosis is currently diagnosed by renal biopsy. Besides being time-consuming, it is an invasive procedure and as such, it implies a risk of complications including bleeding, pain and infection. Hence, much effort has gone into identifying non-invasive markers of fibrosis in blood or urine. The fibrotic process is a cascade of factors including inflammation, tissue hypoxia and various pro-fibrotic cytokines and growth factors [29]. Animal studies of MR antagonism in CNI nephrotoxicity have identified

several markers involved in the fibrogenic process that were regulated by MR antagonists [30]. Simultaneous plasma–urine samples and renal biopsies allow for the possible identification of non-invasive markers of fibrosis. Further, studies of markers in blood and urine might contribute to our understanding of the molecular mechanisms of MR antagonism. Specific markers of interest will be defined when all samples have been obtained.

Safety

Plasma potassium and -creatinine levels are monitored closely at initiation of therapy and after any dose adjustment. Sustained potassium levels > 5.8 mmol/L will result in reduction of dosage to 25 mg per day. In case of hyperkalemia on 25 mg per day, the patient will be withdrawn from the study. Potassium binding resins will only be used to handle cases of acute hyperkalemia, thus chronic treatment with resins is not allowed. Hyperkalemia is registered as an adverse event in case of an absolute increase of > 1.5 mmol/L or any increase to a level above 5.5 mmol/L. All significant increases in plasma creatinine are evaluated by study investigators, and in case of doubt of the etiology, the study drug is discontinued until renal function has stabilized. All adverse events registered throughout participation in the study will be recorded. Serious adverse events are defined according to Good Clinical Practice as events that result in death, are life threatening, require hospitalization, cause prolongation of existing hospitalization or result in persistent or significant disability/incapacity. The project safety board continuously

Table 2 All registered variables

Baseline	Every 3 months	Additionally at 0, 1, 2, 3 years	0 and 2 years (n = 50)
Date of birth			
Sex			
Height			
Smoking			
Number of pack years			
Primary kidney disease			
Previous dialysis			
Transplantation date			
Number of previous transplantations			
Comorbidity			
Apoplexia			
Myocardial infarction/cardiac revascularisation			
Heart failure			
Hypertension			
Diabetes			
Other			
	Current medication	Objective findings	Ambulatory blood pressure
	Symptoms	Heart stethoscopy	SBP
	Dizziness	Lung stethoscopy	DBP
	Fainting	Edema	SBP-day
	Shortness of breath	ECG	SPB-night
	Gynecomasty	Chrom-EDTA clearance	DBP-day
	Impotence		DBP-night
	Others	Blood samples	Average pulse
		CRP	
		Total cholesterol	
		HDL	
		LDL	
		Triglyceride	
		Markers of fibrosis	
	Objective findings		
	Blood pressure (systolic)		
	Blood pressure (diastolic)		
	Pulse		
	Bodyweight		
		24 h urine sample	
		Creatinine clearance	
		Proteinuria	
		U-sodium	
		U-potassium	
		Markers of fibrosis	
	Blood samples		
	Sodium		
	Potassium		
	Creatinine		
	Adverse events		
	Compliance to study drug		

ECG Electrocardiogram, CRP C-reactive protein, HDL High density lipoprotein, LDL Low density lipoprotein, SBP Systolic blood pressure, DBP Diastolic blood pressure

Table 3 Study outcomes

Primary endpoint	Secondary endpoints
Chrome-EDTA clearance	24 h urinary protein excretion
	Renal fibrosis (morphology)
	Cardiovascular events
	Biomarkers of fibrosis in tissue, blood and urine

monitors serious adverse events to identify general study safety issues.

Withdrawal

Withdrawal criteria include a sustained compliance of less than 80%, hyperkalemia despite reduction of dosage or intolerable side effects.

Sample size

Assuming a standard deviation in chrome-EDTA clearance of 10 mL/min, a sample size of 126 patients (63 in each group) will be able to detect a difference in chrome-EDTA clearance of 5 mL/min between the groups with 80% power and a significance level of 0.05. With an expected dropout rate of 15%, the planned total was set to 170 patients.

Allocation and blinding

After completing the baseline workup (Fig. 1), patients are allocated to consecutive randomization numbers. Randomization has been performed by the pharmacy at Odense University Hospital in blocks of four. The allocation code is blinded to both patients and investigators and is solely known by the pharmacy. Opaque envelopes containing the individual allocation are available on site in case of the need for emergency unblinding. If the allocation code is revealed before completing the trial the patient will be excluded.

Data management

All data will be documented for each visit in the respective Case Report Form and subsequently entered into the SPIREN project database. Data will be secured by double entry. The project database has been developed in cooperation with the Database Unit of the Region of Southern Denmark and complies with the standards of Good Clinical Practice.

Statistical methods

All statistical analyses will be done using STATA software. All generated variables will be documented by do-files. The main analysis will be performed as intention-to-treat using last-observation-carried-forward. Sub-analyses will include per protocol analyses and “best case”/“worst case”

analyses. Where appropriate, variables will be analyzed using parametric or non-parametric tests.

Trial status

The first patient was included in January 2013. An interim analysis was performed in September 2015 including 40 patients after two years of participation [31]. The interim analysis evaluated the rates of decline in kidney function between the two groups to ensure the safety of the study drug and found no difference between the two groups. In November 2017 a total of 142 patients were active in the study and 41 baseline biopsies had been performed. Inclusion is expected to be complete by 2018.

Discussion

Long term kidney graft survival is a key issue in transplant medicine. Chronic CNI nephrotoxicity contributes to late allograft loss [3]. There is increasing evidence, that aldosterone plays a role in detrimental processes beyond fluid and sodium homeostasis e.g. inflammation and fibrosis, thereby possibly contributing to allograft failure [7]. Several animal studies have shown an effect of MR antagonism in reducing CNI nephrotoxicity [30]. The few available human studies addressing this hypothesis have been underpowered or focused on short term effects [19, 22]. This study aims to provide sufficiently powered evidence regarding the effect of long term MR antagonism on GFR and the development of kidney fibrosis in prevalent kidney transplant patients.

Concerns have been raised regarding MR antagonism in patients with impaired renal function due to the risk of hyperkalemia, which is a potentially lethal side-effect. In the wake of the Randomized Aldactone Evaluation Study (RALES) - a randomized, clinical trial investigating the effect of spironolactone in patients with congestive heart failure and serum creatinine below 221 $\mu\text{mol/L}$ - there was a significant increase in hospitalizations due to hyperkalemia from 2.4 to 11.0 per 1000 patients [32]. The risk of hyperkalemia increases as GFR deteriorates. One safety study of MR antagonist eplerenone 25 mg/day for 8 weeks in 31 kidney transplant patients found a significant increase in plasma potassium during eplerenone treatment, however there was only one incidence of moderate hyperkalemia (>5.5 mmol/L) and no patients were withdrawn from the study due to hyperkalemia. It was concluded, that MR antagonism is safe in kidney transplant patients with a GFR >30 mL/min, but warrants close monitoring of plasma-potassium [33].

Another concern regarding MR antagonism is the observation that plasma creatinine levels tend to increase at the initiation of therapy. This effect has also been observed in studies of MR antagonism in chronic kidney disease [34]. In RALES, spironolactone significantly increased the occurrence of worsening renal function -

defined as a reduction of eGFR > 30% - however, this did not impact the relative mortality risk in this group. Interestingly, worsening renal function was associated with an increased adjusted mortality risk in the placebo group, but not in the spironolactone group [35]. Although the increase in plasma creatinine is reversible when MR antagonists are discontinued, worsening renal function poses a diagnostic challenge with several possible etiologies in the kidney transplant population (e.g. acute rejection, post-renal obstruction, BK-virus nephropathy etc.). If in doubt, MR antagonists should be discontinued and appropriate diagnostic measures performed.

Despite potential pitfalls using MR antagonists in kidney transplant patients, evidence from animal and small human studies indicate a potential for improving long term allograft function. This study is, to our knowledge, the first to investigate the effect of MR antagonism on long term allograft function in adult kidney transplant patients in a prospective, randomized fashion. Results will contribute to current evidence and possibly influence the future management of kidney transplant patients with regards to improving long term allograft survival.

Abbreviations

CNI: Calcineurin inhibitors; GFR: Glomerular filtration rate; MR: Mineralocorticoid receptor; RALES: The Randomized Aldactone Evaluation Study; TGF- β : Transforming growth factor β

Acknowledgements

Study participants, staff and departments participating in the SPIREN trial are acknowledged for their great efforts to complete this study.

Funding

The SPIREN trial is an investigator initiated trial. Takeda Pharma supplies the trial medication including placebo tablets free of charge, but is otherwise not involved in collecting or analyzing data. Funding has been obtained by grants from the following independent public and private funds: Odense University Hospital Free Research Fund, the Region of Southern Denmark Research- and PhD-funds, the Danish Kidney Association Research Fund, Helen and Einar Bjørnøw's Fund, Danish Society of Nephrology Travel Fund, King Christian X Fund, the Danish Medical Association Research Fund, the Medicine Fund of the Danish Regions and Odense University Hospital Board of Consultants Research Fund. The funding bodies had no influence on the design of the study, the collection, analysis and interpretation of data or in writing the manuscript.

Availability of data and materials

The datasets used and/or analyzed during the current study will be available from the corresponding author on reasonable request.

Authors' contributions

LAM is the coordinating investigator, HT, BT, ME and AF are investigators/subinvestigators in the respective study centers and CB is the sponsor of the study. LAM drafted the manuscript, and all co-authors reviewed and revised the article. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The SPIREN trial has been approved by the Research Ethics Committee of Southern Denmark on the 24th of August 2011 (project ID: s-20110095, protocol version 2 (07/28/2011)). Oral and written informed consent to participation is obtained from all study participants by study personnel prior to any study related procedure. All participants receive both written and oral information about the study before giving consent. The trial is conducted according to the standards of Good Clinical Practice (GCP) and undergoes continuous monitoring by local GCP representatives.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Department of Nephrology, Odense University Hospital, Sdr. Boulevard 29, DK-5000 Odense C, Denmark. ²Department of Clinical Research, University of Southern Denmark, Winsløwparken 19, 3. Sal, 5000 Odense C, Denmark. ³Department of Nephrology, Kolding Hospital, Sygehusvej 24, 6000 Kolding, Denmark. ⁴Department of Nephrology, Rigshospitalet, Blegdamsvej 9, 2100 København Ø, Denmark. ⁵Department of Nephrology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200 Aarhus N, Denmark.

Received: 21 December 2017 Accepted: 26 March 2018

Published online: 03 May 2018

References

- Calne RY, White DJ, Thiru S, Evans DB, McMaster P, Dunn DC, et al. Cyclosporin a in patients receiving renal allografts from cadaver donors. *Lancet*. 1978;2:1323–7.
- Starzl TE, Todo S, Fung J, Demetris AJ, Venkataraman R, Jain A. FK 506 for liver, kidney, and pancreas transplantation. *Lancet*. 1989;2:1000–4.
- Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. *Clin J Am Soc Nephrol*. 2009;4:481–508.
- Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. *Transplantation*. 2004;78:557–65.
- Nankivell BJ, P'Ng CH, O'Connell PJ, Chapman JR. Calcineurin inhibitor nephrotoxicity through the lens of longitudinal histology: comparison of cyclosporine and tacrolimus eras. *Transplantation*. 2016;100:1723–31.
- Jaisser F, Farman N. Emerging roles of the mineralocorticoid receptor in pathology: toward new paradigms in clinical pharmacology. *Pharmacol Rev*. 2016;68:49–75.
- Brown NJ. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. *Nat Rev Nephrol*. 2013;9:459–69.
- Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone evaluation study investigators. *N Engl J Med*. 1999;341:709–17.
- Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. *N Engl J Med*. 2003;348:1309–21.
- Richards AM, Nicholls MG. Aldosterone antagonism in heart failure. *Lancet*. 1999;354:789–90.
- Bolignano D, Palmer SC, Navaneethan SD, Strippoli GFM. Aldosterone antagonists for preventing the progression of chronic kidney disease. *Cochrane Database Syst Rev*. 2014;(4):CD007004. doi:<https://doi.org/10.1002/14651858.CD007004.pub3>.
- Perez-Rojas JM, Derive S, Blanco JA, Cruz C, Martinez de la Maza L, Gamba G, et al. Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic cyclosporine nephrotoxicity. *Am J Physiol Renal Physiol*. 2005;289:F1020–30.
- Nielsen FT, Jensen BL, Marcussen N, Skott O, Bie P. Inhibition of mineralocorticoid receptors with eplerenone alleviates short-term cyclosporin a nephrotoxicity in conscious rats. *Nephrol Dial Transplant*. 2008;23:2777–83.
- McAuley FT, Whiting PH, Thomson AW, Simpson JG. The influence of enalapril or spironolactone on experimental cyclosporin nephrotoxicity. *Biochem Pharmacol*. 1987;36:699–703.
- Feria I, Pichardo I, Juarez P, Ramirez V, Gonzalez MA, Uribe N, et al. Therapeutic benefit of spironolactone in experimental chronic cyclosporine a nephrotoxicity. *Kidney Int*. 2003;63:43–52.
- Perez-Rojas J, Blanco JA, Cruz C, Trujillo J, Vaidya VS, Uribe N, et al. Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity. *Am J Physiol Renal Physiol*. 2007;292:F131–9.

17. Macunluoglu B, Arikan H, Atakan A, Tuğlular S, Ülfer G, Cakalagaoglu F, et al. Effects of spironolactone in an experimental model of chronic cyclosporine nephrotoxicity. *Transplant Proc.* 2008;40:273–8.
18. Nielsen FT, Jensen BL, Hansen PB, Marcussen N, Bie P. The mineralocorticoid receptor antagonist eplerenone reduces renal interstitial fibrosis after long-term cyclosporine treatment in rat: antagonizing cyclosporine nephrotoxicity. *BMC Nephrol.* 2013;14:42.
19. Medeiros M, Velasquez-Jones L, Hernandez AM, Ramon-Garcia G, Valverde S, Fuentes Y, et al. Randomized controlled trial of mineralocorticoid receptor blockade in children with chronic kidney allograft nephropathy. *Clin J Am Soc Nephrol.* 2017;12:1291–300.
20. Gonzalez Monte E, Andres A, Polanco N, Toribio MJ, Santana R, Gutierrez Martinez E, et al. Addition of spironolactone to dual blockade of renin angiotensin system dramatically reduces severe proteinuria in renal transplant patients: an uncontrolled pilot study at 6 months. *Transplant Proc.* 2010;42:2899–901.
21. de Sousa MV, Guida JP, do Valle CF, Camargo LF, Rivelli GG, Mazzali M. Spironolactone in post-transplant proteinuria: a safe alternative therapy. *Transplant Proc.* 2017;49:813–6.
22. Ojeda-Cervantes M, Barrera-Chimal J, Alberu J, Perez-Villalva R, Morales-Buenrostro LE, Bobadilla NA. Mineralocorticoid receptor blockade reduced oxidative stress in renal transplant recipients: a double-blind, randomized pilot study. *Am J Nephrol.* 2013;37:481–90.
23. Marcen R, Morales JM, Fernandez-Rodriguez A, Capdevila L, Pallardo L, Plaza JJ, et al. Long-term graft function changes in kidney transplant recipients. *NDT Plus.* 2010;3:ii2–8.
24. Gill JS, Tonelli M, Mix CH, Pereira BJ. The change in allograft function among long-term kidney transplant recipients. *J Am Soc Nephrol.* 2003;14:1636–42.
25. Kasiske BL, Gaston RS, Gourishankar S, Halloran PF, Matas AJ, Jeffery J, et al. Long-term deterioration of kidney allograft function. *Am J Transplant.* 2005;5:1405–14.
26. Gera M, Slezak JM, Rule AD, Larson TS, Stegall MD, Cosio FG. Assessment of changes in kidney allograft function using creatinine-based estimates of glomerular filtration rate. *Am J Transplant.* 2007;7:880–7.
27. Fleming JS, Zivanovic MA, Blake GM, Burniston M, Cosgriff PS, British Nuclear Medicine S. Guidelines for the measurement of glomerular filtration rate using plasma sampling. *Nucl Med Commun.* 2004;25:759–69.
28. Ellingsen AR, Nyengaard JR, Osterby R, Jorgensen KA, Petersen SE, Marcussen N. Measurements of cortical interstitium in biopsies from human kidney grafts: how representative and how reproducible? *Nephrol Dial Transplant.* 2002;17:788–92.
29. Liu Y. Cellular and molecular mechanisms of renal fibrosis. *Nat Rev Nephrol.* 2011;7:684–96.
30. Mortensen LA, Bstrup C, Thiesson HC. Does mineralocorticoid receptor antagonism prevent Calcineurin inhibitor-induced nephrotoxicity? *Frontiers in Medicine.* 2017;4:210.
31. Mortensen L, Bstrup C, Nielsen FT, Halekoh U, Jensen BL, Marcussen N, et al. The effect of spironolactone on calcineurin inhibitor induced nephrotoxicity. *Am J transplant journal translated name. Am J Transplant.* 2016;16:486.
32. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. Rates of hyperkalemia after publication of the randomized Aldactone evaluation study. *N Engl J Med.* 2004;351:543–51.
33. Bertocchio JP, Barbe C, Lavaud S, Toupance O, Nazeyrollas P, Jaisser F, et al. Safety of Eplerenone for kidney-transplant recipients with impaired renal function and receiving cyclosporine a. *PLoS One.* 2016;11:e0153635.
34. Boesby L, Elung-Jensen T, Klausen TW, Strandgaard S, Kamper AL. Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study. *PLoS One.* 2011;6:e26904.
35. Vardeny O, Wu DH, Desai A, Rossignol P, Zannad F, Pitt B, et al. Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (randomized Aldactone evaluation study). *J Am Coll Cardiol.* 2012;60:2082–9.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

